Impact of smoking on stage-specific survival in human papilloma virus-associated oropharyngeal squamous cell carcinoma.
Peter Horwich, Abhijit Gundale, Stephen Patin, Jose Flores, Tara Moore Medlin, Brent A Chang, Cherie-Ann O Nathan
Author Information
Peter Horwich: Department of Otolaryngology - Head and Neck Surgery, Louisiana State University Health Sciences Center & Feist-Weiller Cancer Center, Shreveport, Louisiana, USA. ORCID
Abhijit Gundale: Department of Otolaryngology - Head and Neck Surgery, Louisiana State University Health Sciences Center & Feist-Weiller Cancer Center, Shreveport, Louisiana, USA. ORCID
Stephen Patin: Department of Otolaryngology - Head and Neck Surgery, Louisiana State University Health Sciences Center & Feist-Weiller Cancer Center, Shreveport, Louisiana, USA.
Jose Flores: Yale University School of Medicine, New Haven, Connecticut, USA.
Tara Moore Medlin: Department of Otolaryngology - Head and Neck Surgery, Louisiana State University Health Sciences Center & Feist-Weiller Cancer Center, Shreveport, Louisiana, USA.
Brent A Chang: Department of Otolaryngology - Head and Neck Surgery, Louisiana State University Health Sciences Center & Feist-Weiller Cancer Center, Shreveport, Louisiana, USA. ORCID
Cherie-Ann O Nathan: Department of Otolaryngology - Head and Neck Surgery, Louisiana State University Health Sciences Center & Feist-Weiller Cancer Center, Shreveport, Louisiana, USA. ORCID
BACKGROUND: The American Joint Committee on Cancer (AJCC) released a new staging system for human papilloma virus (HPV) positive oropharyngeal cancer (OPC) in their eighth edition. The role of smoking in HPV positive oropharyngeal cancer remains controversial and is not factored into the updated staging system. METHODS: Single institutional, retrospective chart review of patients with HPV positive OPC from 2009 to 2017 was completed. Dichotomized smoking data were collected into 0-9 and ≥10 pack-year histories. Kaplan-Meier survival curves compared overall survival (OS) for smokers and nonsmokers. RESULTS: Five-year OS was not statistically different in stage I or stage II HPV positive OPC comparing nonsmokers versus smokers, but worse in stage III smokers (38% vs. 76%, p < 0.05). CONCLUSION: Greater than 10 pack-year smoking status may negatively affect survival in late stage HPV positive OPC but not in early stage disease. HPV positive smokers may require additional risk stratification.
Beynon RA, Lang S, Schimansky S, et al. Tobacco smoking and alcohol drinking at diagnosis of head and neck cancer and all-cause mortality: results from head and neck 5000, a prospective observational cohort of people with head and neck cancer: smoking status and alcohol intake on HNC survival. Int J Cancer. 2018;143(5):1114-1127.
Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
O'Sullivan B, Huang SH, Su J, et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440-451. https://doi.org/10.1016/S1470-2045(15)00560-4.
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999-2016) www.cdc.gov/cancer/dataviz
Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24-35.
Gillison ML, Zhang Q, Jordan R, et al. Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. JCO. 2012;30(17):2102-2111.
Xiao R, Pham Y, Ward MC, et al. Impact of active smoking on outcomes in HPV+ oropharyngeal cancer. Head Neck. 2020;42(2):269-280.
Vawda N, Banerjee RN, Debenham BJ. Impact of smoking on outcomes of HPV-related oropharyngeal cancer treated with primary radiation or surgery. Int J Radiat Oncol Biol Phys. 2019;103(5):1125-1131.
Peppone LJ, Mustian KM, Morrow GR, et al. The effect of cigarette smoking on cancer treatment-related side effects. Oncologist. 2011;16(12):1784-1792.
Chen AM, Daly ME, Farwell DG, et al. Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy. JAMA Otolaryngol Head Neck Surg. 2014;140(2):129.
Lassen P, Lacas B, Pignon J-P, et al. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: the MARCH-HPV project. Radiother Oncol. 2018;126(1):107-115.
Cramer JD, Hicks KE, Rademaker AW, Patel UA, Samant S. Validation of the eighth edition American Joint Committee on Cancer staging system for human papillomavirus-associated oropharyngeal cancer. Head Neck. 2018;40(3):457-466.
Chen SY, Massa S, Mazul AL, et al. The association of smoking and outcomes in HPV-positive oropharyngeal cancer: a systematic review. Am J Otolaryngol. 2020;41(5):102592. https://doi.org/10.1016/j.amjoto.2020.102592.
Ference R, Liao D, Gao Q, Mehta V. Impact of smoking on survival outcomes in HPV-related oropharyngeal carcinoma: a meta-analysis. Otolaryngol Head Neck Surg. 2020;163:1114-1122. https://doi.org/10.1177/0194599820931803.
